Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study

Journal of the American College of Cardiology

Volumn 47, Issue 11, 2006, Pages 2326-2331

  Scirica, Benjamin M ^a   Morrow, David A ^a   Cannon, Christopher P ^a   Ray, Kausik K ^a   Sabatine, Marc S ^a   Jarolim, Petr ^a   Shui, Amy ^a   McCabe, Carolyn H ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HAZARD ASSESSMENT; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ACUTE DISEASE; CARDIAC OUTPUT, LOW; CORONARY DISEASE; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NATRIURETIC PEPTIDE, BRAIN; PRAVASTATIN; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SYNDROME;

EID: 33646923161     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.03.034     Document Type: Article

References (26)

1. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
2. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
3. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
4. Horwich T.B., Hamilton M.A., Maclellan W.R., and Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
5. Laaksonen R., Jokelainen K., Laakso J., et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 77 (1996) 851-854
6. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
8. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
9. Lewis E.F., Moye L.A., Rouleau J.L., et al. Predictors of late development of heart failure in stable survivors of myocardial infarction. the CARE study. J Am Coll Cardiol 42 (2003) 1446-1453
10. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER). a randomised controlled trial. Lancet 360 (2002) 1623-1630
11. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
12. Haim M., Battler A., Behar S., et al. Acute coronary syndromes complicated by symptomatic and asymptomatic heart failure. does current treatment comply with guidelines?. Am Heart J 147 (2004) 859-864
13. Kashani A., Giugliano R.P., Antman E.M., et al. Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. Eur Heart J 25 (2004) 1702-1710
14. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
15. Morrow D.A., de Lemos J.A., Blazing M.A., et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 294 (2005) 2866-2871
16. Cannon C.P., McCabe C.H., Belder R., Breen J., and Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 89 (2002) 860-861
17. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
18. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110 (2002) 285-288
19. Rikitake Y., and Liao J.K. Rho GTPases, statins, and nitric oxide. Circ Res 97 (2005) 1232-1235
20. Sola S., Muhammad Q.S., Lerakis S., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
21. Horwich T.B., MacLellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
22. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
23. Ray J.G., Gong Y., Sykora K., and Tu J.V. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165 (2005) 62-67
24. Mozaffarian D., Minami E., Letterer R.A., Lawler R.L., McDonald G.B., and Levy W.C. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 96 (2005) 1699-1704
25. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47 (2006) 338-341
26. Ramasubbu K., and Mann D.L. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol 47 (2006) 342-344